Related Experiment Videos
Ryanodine receptor-targeted anti-arrhythmic therapy.
Xander H T Wehrens1, Stephan E Lehnart, Andrew R Marks
1Department of Physiology and Cellular Biophysics, Center for Molecular Cardiology, College of Physicians and Surgeons of Columbia University, New York, New York 10032, USA.
Annals of the New York Academy of Sciences
|August 12, 2005
Summary
Altered calcium handling in heart failure and CPVT causes fatal arrhythmias. New therapies target defective calcium release from the sarcoplasmic reticulum to prevent sudden cardiac death.
Area of Science:
- Cardiology
- Molecular Biology
- Genetics
Background:
- Cardiac arrhythmias, particularly in heart failure (HF) and inherited syndromes like catecholaminergic polymorphic ventricular tachycardia (CPVT), are significant causes of mortality.
- Intracellular calcium handling is critical in the development of cardiac arrhythmias.
Purpose of the Study:
- To investigate the role of sarcoplasmic reticulum (SR) calcium leak via cardiac ryanodine receptors (RyR2) in HF and CPVT-related arrhythmias.
- To explore novel therapeutic strategies targeting SR Ca(2+) release defects.
Main Methods:
- Analysis of intracellular calcium handling mechanisms in cardiac cells.
- Investigation of RyR2 function in models of heart failure and CPVT.
- Evaluation of potential therapeutic interventions.
Main Results:
- Diastolic calcium leak from the SR through RyR2 can trigger delayed afterdepolarizations and arrhythmias in HF.
- Mutant RyR2 channels causing SR Ca(2+) leak are implicated in exercise-induced arrhythmias in CPVT patients.
- Understanding these Ca(2+) leak mechanisms provides a basis for new therapeutic approaches.
Conclusions:
- Defective SR Ca(2+) release, specifically SR Ca(2+) leak via RyR2, is a key mechanism in life-threatening arrhythmias in HF and CPVT.
- Targeting these calcium handling abnormalities offers a promising therapeutic avenue for preventing sudden cardiac death in these conditions.